All In Biotech

Drug Trial Radar · NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

A Randomized Clinical Trial of Antioxidants to Prevent Preeclampsia and An Observational Cohort Study to Predict Preeclampsia

Last checked: Nov 19, 2026Latest source record: Feb 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,154

Actual

Start

Jun 2003

Primary completion

Oct 2008

Study completion Jan 2009

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Aug 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Preeclampsia is one of the most common complications of pregnancy and is characterized by high blood pressure and protein in the urine. This can cause problems in the second half of pregnancy for both the mother and fetus. This study of preeclampsia consists of two parts: 1) a randomized, placebo controlled, multicenter clinical trial of 10,000 low-risk nulliparous women between 9 and 16 weeks gestation and 2) an observational, cohort study of 4,000 patients between 9 and 12 weeks gestation who are also enrolled in the trial. Subjects in both parts will receive either 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo daily. The purpose of the randomized, clinical trial is to find out if high doses of vitamin C and E will reduce the risk of preeclampsia and other problems associated with the disease. The study will also evaluate the safety of antioxidant therapy for mother and infant. Patients will be seen monthly to receive their supply of study drug, to have weight and blood pressure recorded, to have urine protein measured, and to assess any side effects. At two visits, blood and urine will be collected. The observational, cohort study will prospectively measure potential biochemical and biophysical markers that might predict preeclampsia. These patients will have additional procedures including uterine artery Doppler and blood drawn for a complete blood count (CBC).

Conditions

  • Preeclampsia

Interventions

  • Dietary Supplement/VitaminsDrug

    Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.

  • Placebo for Vitamin C and Vitamin EDrug

    Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or NeonateTime frame: 20 weeks through discharge following delivery
  2. Severe HypertensionTime frame: 20 weeks through discharge following delivery
  3. Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme LevelsTime frame: 20 weeks through discharge following delivery
  4. Severe or Mild Pregnancy-associated Hypertension With ThrombocytopeniaTime frame: 20 weeks through discharge following delivery
  5. Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine LevelTime frame: 20 weeks through discharge following delivery
  6. Severe or Mild Pregnancy-associated Hypertension With an Eclamptic SeizureTime frame: 20 weeks through discharge following delivery
  7. Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related DisordersTime frame: 20 weeks through discharge following delivery
  8. Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic GroupTime frame: 20 weeks through discharge following delivery
  9. Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal DeathTime frame: 20 weeks through discharge or prior to discharge following delivery admission

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Northwestern University

    Chicago, Illinois

  • Wayne State University

    Detroit, Michigan

  • Columbia University

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Case Western University

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Oregon Health and Sciences University

    Portland, Oregon

  • Drexel University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Magee Womens Hospital

    Pittsburgh, Pennsylvania

  • Brown University

    Providence, Rhode Island

  • University of Texas - Southwest

    Dallas, Texas

  • University of Texas Medical Branch

    Galveston, Texas

  • University of Texas - Houston

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.